Ex vivo simulation of the action of antileukemia drugs by measuring apoptosis-related mRNA in blood

Clinical Chemistry

Volumn 54, Issue 4, 2008, Pages 673-681

  Mitsuhashi, Masato ^a,b   Endo, Katsuya ^b   Obara, Kazuhiko ^b   Izutsu, Hiroshi ^b   Ishida, Taishi ^c   Chikatsu, Norio ^c   Shinagawa, Atsushi ^c  

^a Hitachi Chemical Research Center   (United States)

^b HITACHI LTD   (Japan)

^c Hitachi   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; ANTILEUKEMIC AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; LIPOCORTIN 5; MESSENGER RNA; MITOXANTRONE; PREDNISONE; PROTEIN P53; PUMA PROTEIN; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BBC3 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ONCOPROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER REGRESSION; CELL CYCLE ARREST; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOASSAY; MALE; NUCLEOSOME; SIMULATION; TREATMENT RESPONSE; BLOOD; GENETICS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER;

EID: 42449125657     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2007.091975     Document Type: Article

References (15)

1. Jain KK. Personalized medicine. Curr Opin Mol Ther 2002;4:548-58.
2. Di Paolo A, Danesi R, Del Tacca M. Pharmacogenetics of neoplastic diseases: new trends. Pharmacol Res 2004;49:331-42.
3. Chiaretti S, Li X, Gentleman R, Vitale A, Vignetti M, Mandelli F, et al. Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood 2004;103:2771-8.
4. Zittoun R, Bouchard M, Facquet-Danis J, Perciedu-Sert M, Bousser J. Prediction of the response to chemotherapy in acute leukemia. Cancer 1975;35:507-13.
5. Mitsuhashi M, Endo K, Obara K, Izutsu H, Ishida T, Chikatsu N, Shinagawa A. Quantification of drug-induced mRNA in human whole blood ex vivo. Clin Med: Blood Disorders 2008;1:1-11.
6. 1 cyclin-dependent kinases. Cell 1993;75:805-16.
7. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, et al. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995;267:1018-21.
8. Villunger A, Michalak EM, Coultas L, Müllauer F, Böck G, Ausserlechner MJ, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003;302:1036-8.
9. Vousden KH. Apoptosis. p53 and PUMA: a deadly duo. Science 2005;309:1685-6.
10. Mitsuhashi M, Tomozawa S, Endo K, Shinagawa A. Quantification of mRNA in whole blood by assessing recovery of RNA and efficiency of cDNA synthesis. Clin Chem 2006;52:634-42.
11. Mitsuhashi M. Ex vivo simulation of drug action: quantification of drug-induced mRNA as a bridge between preclinical and clinical trials. Clin Chem 2007;53:148-9.
12. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106:1154-63.
13. Veuger MJ, Honders MW, Spoelder HE, Willemze R, Barge RM. Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines. Leuk Res 2003;27:445-53.
14. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007;117:112-21.
15. Lotfi K, Zackrisson AL, Peterson C. Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance. Cancer Lett 2002;178:141-9.